Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Purpose: Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy in a global patient population with HER2-positive mBC. Methods: In this open-label, single-arm, multicenter, phase 3b study, eligible patients were ≥ 18 years old with histologically/cytologically confirmed previously untreated HER2-positive mBC. All received ≥ 1 subcutaneous trastuzumab 600 mg fixed dose plus intravenous pertuzumab (loading dose: 840 mg/kg; maintenance: 420 mg/kg) and docetaxel (≥ 6 cycles; initial dose 75 mg/m 2 ) every 3 weeks. The primary objective was safety and tolerability; secondary objectives included efficacy. Results: At clinical cutoff, 276 patients had completed the study; median duration of follow-up was 27 months. The most common any-grade adverse events were diarrhea, alopecia, and asthenia; the most common grade ≥ 3 events were neutropenia, febrile neutropenia, and hypertension. There were no cardiac deaths and mean left ventricular ejection fraction was stable over time. Median investigator-assessed progression-free survival was 18.7 months; objective response rate was 75.6%. Conclusions: Safety and efficacy with subcutaneous trastuzumab plus intravenous pertuzumab and docetaxel in mBC are consistent with historical evidence of intravenous trastuzumab with this combination. Findings further support subcutaneous administration not affecting safety/efficacy profiles of trastuzumab in HER2-positive BC with increased flexibility in patient care. A fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection has recently been approved for the treatment of HER2-positive early/mBC, further addressing the increasing relevance of and need for patient-centric treatment strategies. Trial registration: NCT02402712
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationSwain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30863-0 · Cited by 922
Self-citationIsmael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
A recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis
Wang, Y., Zhao, G., Condello, S., Huang, H., Cardenas, H., Tanner, E. J., Wei, J., Ji, Y., Li, J., Tan, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1488 · Cited by 243
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu364 · Cited by 177
Self-citation
Research works printed but not linked: 1
- APM Health Europe (2020) Treating patients at home with subcutaneous injections of Roche’s Herceptin Hyclecta saves money [press review]. 31 January, 2020. https://www.apmhealtheurope.com/freestory/0/67360/treating-patients-at-home-with-subcutaneous-injections-of-roche-s-herceptin-hylecta-saves-money. Accessed November 2020
Cited by
Bienia, A., Wiecheć-Cudak, O., Murzyn, A. A., & Krzykawska-Serda, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081147 · Cited by 68
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Gameiro, S. R., Strauss, J., Gulley, J. L., & Schlom, J. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221089910 · Cited by 36
Immunotherapy for HER-2 positive breast cancer
Yang, T., Kang, L., Li, D., & Song, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1097983 · Cited by 33
Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology
Jacquot, G., Navarro, P. L., Grange, C., Boudali, L., Harlepp, S., Pivot, X. B., & Detappe, A. (2024) · Advanced Materials · doi:10.1002/adma.202406604 · Cited by 27
Metadata
- Authors
- Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., Karaszewska, B., Juárez-Ramiro, A., Morales-Vásquez, F., Pérez-García, J. M., Cardona-Huerta, S., Monturus, E., Sequi, M., Restuccia, E., Benyunes, M., & Martín, M.
- Affiliations
- Ospedale Papa Giovanni XXIII (IT)
- Velindre Cancer Centre (GB)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Central Clinical Hospital (PL)
- National Institute of Oncology (HU)
- Instituto Nacional de Cancerología (MX)
- F. Hoffmann-La Roche AG (CH)
- Genentech (US)
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- Breast Cancer Research and Treatment
- Published
- 2021-03-21
- Volume
- 187
- Issue
- 2
- Pages
- 467-476
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC8189949
- OpenAlex
- W3137191916
- Cited by
- 22
- References
- 27
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 3
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Breast Cancer Research and Treatment (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- F. Hoffmann-La Roche Ltd.
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- HER2-positive metastatic breast cancer, subcutaneous trastuzumab, pertuzumab, docetaxel, safety and tolerability, fixed-dose combination, progression-free survival, objective response rate, neutropenia, cardiac safety
- MeSH terms
- Trastuzumab, Docetaxel, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Stroke Volume, Biomarkers, Tumor, Ventricular Function, Left, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. https://app.cochat.ai/papers/10.1007/s10549-021-06145-3
- The paper
- Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., Karaszewska, B., Juárez-Ramiro, A., Morales-Vásquez, F., Pérez-García, J. M., Cardona-Huerta, S., Monturus, E., Sequi, M., Restuccia, E., Benyunes, M., & Martín, M. (2021). Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-021-06145-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.